Numerous studies have shown that targeted therapy with EGFR-TKIs has achieved favorable PFS in NSCLC patients with EGFR mutation (in particular, exon 19 deletion or exon 21 L858R), however, acquired resistance occurs in most patients after 9-12 months treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.